| Impact of Intravitreal Bevacizumab Injection on Life Quality in Patients with Branch Retinal Vein Occlusion. |
|
Jee Wook Kim, Kyung Seek Choi, Mi Ri Rhee, Sung Jin Lee |
1Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea. wismile@schmc.ac.kr
2Myeong Eye Clinic, Seoul, Korea. |
| 망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 베바시주맙 주입술이 삶의 질에 미치는 영향 |
|
김지욱1⋅최경식1⋅이미리2⋅이성진1 |
Department of Ophthalmology, Soonchunhyang University College of Medicine1, Seoul, Korea
Myeong Eye Clinic2, Seoul, Korea |
|
|
| Abstract |
PURPOSE
To evaluate the impact of intravitreal bevacizumab injection on visual function and vision-related quality of life (VR-QOL) in patients with branch retinal vein occlusion (BRVO) using the Korean version of the National Eye Institute Visual Function Questionnaire 25 (K-NEI-VFQ-25). METHODS: This study included 32 normal control subjects and 32 patients with BRVO. The Korean version of NEI-VFQ-25 was answered by the patients with BRVO before and 3 months after intravitreal bevacizumab injection, as well as by normal control subjects. Clinical data were collected, including central macular thickness (CMT), total macular volume (TMV) (using time-domain optical coherence tomography [OCT]), and best corrected visual acuity (BCVA). RESULTS: Visual acuity, CMT, and TMV significantly improved 3 months after intravitreal bevacizumab injections. No bevacizumab-related systemic or ocular adverse effects following intravitreal drug injections were observed. Significant improvement in the VFQ-25 composite score was observed in patients with BRVO. Subscale scores, including general vision, near activities, distance activities, social functioning, mental health, role difficulties, dependency, and peripheral vision, improved after injection. However, subscale scores regarding general health, ocular pain, driving, and color vision did not improve significantly. CONCLUSIONS: Intravitreal bevacizumab injection appears to be an effective treatment for visual function, as well as VR-QOL in macular edema secondary to BRVO. However, improvement of driving function and color vision appears to require a longer recovery time than visual function. |
| Key Words:
Bevacizumab;BRVO;VR-QOL |
|
PDF Links
Full text via DOI
Download Citation
